Equities

Orexo AB

Orexo AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)9.55
  • Today's Change0.150 / 1.60%
  • Shares traded11.65k
  • 1 Year change-35.82%
  • Beta0.8180
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Orexo AB has grown net income from a loss of -177.60m to a smaller loss of -128.30m despite relatively flat revenues.
Gross margin88.28%
Net profit margin-17.67%
Operating margin-8.53%
Return on assets-13.45%
Return on equity-325.00%
Return on investment-20.81%
More ▼

Cash flow in SEKView more

In 2023, Orexo AB increased its cash reserves by 29.35%, or 38.80m. Cash Flow from Investing totalled 200.80m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 95.00m for operations while cash used for financing totalled 70.10m.
Cash flow per share-0.638
Price/Cash flow per share--
Book value per share-0.7896
Tangible book value per share-4.93
More ▼

Balance sheet in SEKView more

Orexo AB has a Debt to Total Capital ratio of 104.80%, a lower figure than the previous year's 497.17%.
Current ratio1.70
Quick ratio1.47
Total debt/total equity--
Total debt/total capital1.05
More ▼

Growth rates in SEK

Year on year, growth in earnings per share excluding extraordinary items increased 27.89%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
47.95
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.